mahatinib

**Mahatinib**, also known as (R)-9b or AB-110, is a novel small molecule inhibitor targeting ACK1 (activated Cdc42-associated kinase 1), a non-receptor tyrosine kinase implicated in prostate cancer progression and drug resistance in breast and lung cancers. Developed as a highly selective inhibitor, it demonstrates dual activity against ACK1-dependent signaling pathways that drive oncogenic processes, positioning it as a potential therapeutic for advanced solid tumors, particularly prostate cancer. It is currently under investigation in early-phase clinical trials, such as NCT03483324 for adults with advanced solid tumors and NCT06705686 (Phase 1) specifically for prostate cancer, with preclinical data supporting its efficacy in overcoming resistance mechanisms.

Other names

(R)-9b9bMS